Background: The management and indication of empiric treatment in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp)-colonized patients should be improved. Methods: A prospective cohort of 94 patients colonized by KPC-Kp was followed for 90 days to validate (i) the Giannella risk score (GRS) to predict the development of any type of KPC-Kp infection and (ii) the INCREMENT-CPE score (ICS) to predict 30-day mortality in patients with infection. Both scores were combined to recommend appropriate empiric treatment. The predictive ability of the scores was measured by calculating the area under the receiver operating characteristic (AUROC) curve. Results: The GRS showed an AUROC curve for infection due to KPC-Kp of 0.92 (95% confidence interval [CI], .87-.98). The optimal cutoff point was fixed at <7 and ≥7 (92.9% sensitivity, 84.8% specificity); infection developed in 6.3% patients in the 0-6 GRS group and in 84.8% patient in the ≥7 GRS group. According to the ICS, the severity of the infection was also significantly higher in the ≥7 GRS group. The ICS showed an AUROC of 0.78 (95% CI, .65-.91) for 30-day all-cause mortality among patients with infection. A classification and regression tree analysis confirmed the GRS cutoff point at 7, and selected ≥12 points to predict a KPC-Kp infection with a high ICS. Conclusions: Our results validate the GRS and ICS for indicating empiric therapy in KPC-Kp-colonized patients.
Background: The management and indication of empiric treatment in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp)-colonized patients should be improved. Methods: A prospective cohort of 94 patients colonized by KPC-Kp was followed for 90 days to validate (i) the Giannella risk score (GRS) to predict the development of any type of KPC-Kp infection and (ii) the INCREMENT-CPE score (ICS) to predict 30-day mortality in patients with infection. Both scores were combined to recommend appropriate empiric treatment. The predictive ability of the scores was measured by calculating the area under the receiver operating characteristic (AUROC) curve. Results: The GRS showed an AUROC curve for infection due to KPC-Kp of 0.92 (95% confidence interval [CI], .87-.98). The optimal cutoff point was fixed at <7 and ≥7 (92.9% sensitivity, 84.8% specificity); infection developed in 6.3% patients in the 0-6 GRS group and in 84.8% patient in the ≥7 GRS group. According to the ICS, the severity of the infection was also significantly higher in the ≥7 GRS group. The ICS showed an AUROC of 0.78 (95% CI, .65-.91) for 30-day all-cause mortality among patients with infection. A classification and regression tree analysis confirmed the GRS cutoff point at 7, and selected ≥12 points to predict a KPC-Kp infection with a high ICS. Conclusions: Our results validate the GRS and ICS for indicating empiric therapy in KPC-Kp-colonized patients.
Authors: Juan González Del Castillo; Agustín Julián-Jiménez; Julio Javier Gamazo-Del Rio; Eric Jorge García-Lamberechts; Ferrán Llopis-Roca; Josep María Guardiola Tey; Mikel Martínez-Ortiz de Zarate; Carmen Navarro Bustos; Pascual Piñera Salmerón; Jesús Álvarez-Manzanares; María Del Mar Ortega Romero; Martin Ruiz Grinspan; Susana García Gutiérrez; Francisco Javier Martín-Sánchez; Francisco Javier Candel González Journal: Eur J Clin Microbiol Infect Dis Date: 2019-11-13 Impact factor: 3.267
Authors: Francisco Rivera-Espinar; Isabel Machuca; Rocio Tejero; Jorge Rodríguez; Ana Mula; Eduardo Marfil; Ángela Cano; Belén Gutiérrez-Gutiérrez; Marina Rodríguez; Juan Carlos Pozo; Carmen De la Fuente; Jesús Rodriguez-Baño; Luis Martínez-Martínez; Rafael León; Julian Torre-Cisneros Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191
Authors: Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Sahil Bhatia; Sarah M Melvin; Samuel P Simon; Joshua R Rosenberg; Molly E Steed; Sandra J Estrada; Taylor Morrisette; Susan L Davis; Michael J Rybak Journal: Infect Dis Ther Date: 2020-02-22
Authors: Oliver A Cornely; José M Cisneros; Julian Torre-Cisneros; María Jesús Rodríguez-Hernández; Luis Tallón-Aguilar; Esther Calbo; Juan P Horcajada; Christian Queckenberg; Ulrike Zettelmeyer; Dorothee Arenz; Clara M Rosso-Fernández; Silvia Jiménez-Jorge; Guy Turner; Susan Raber; Seamus O'Brien; Alison Luckey Journal: J Antimicrob Chemother Date: 2020-03-01 Impact factor: 5.790
Authors: János Juhász; Balázs Ligeti; Márió Gajdács; Nóra Makra; Eszter Ostorházi; Ferenc Balázs Farkas; Balázs Stercz; Ákos Tóth; Judit Domokos; Sándor Pongor; Dóra Szabó Journal: Antibiotics (Basel) Date: 2021-03-07